- Home
- ABBV vs PFE Comparison
ABBV vs PFE Comparison
Compare ABBV & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABBV | PFE |
|---|---|---|
| Founded | 2012 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.9B | 155.0B |
| IPO Year | 2012 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ABBV | PFE |
|---|---|---|
| Price | $227.71 | $27.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 12 |
| Target Price | ★ $247.06 | $27.83 |
| AVG Volume (30 Days) | 5.6M | ★ 31.7M |
| Earning Date | 04-13-2026 | 05-04-2026 |
| Dividend Yield | 3.05% | ★ 6.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.36 | 1.36 |
| Revenue | $61,160,000,000.00 | ★ $62,579,000,000.00 |
| Revenue This Year | $11.90 | N/A |
| Revenue Next Year | $8.24 | N/A |
| P/E Ratio | $96.45 | ★ $19.93 |
| Revenue Growth | ★ 8.57 | N/A |
| 52 Week Low | $164.39 | $20.92 |
| 52 Week High | $244.81 | $27.94 |
Technical Indicators
Market Signals| Indicator | ABBV | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 56.05 |
| Support Level | $220.11 | $24.99 |
| Resistance Level | $229.94 | $27.67 |
| Average True Range (ATR) | 4.76 | 0.51 |
| MACD | -0.43 | -0.05 |
| Stochastic Oscillator | 42.68 | 76.29 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.